American Oncology Network, Inc.

American Oncology Network, Inc., through its subsidiaries, provides oncology services in the United States. The company provides various services to patients, including laboratory services for routine and specialized testing; in-house professional and technical pathology services with complete, accurate and timely pathology reports; in-house specialty pharmacy services with patient education, financial assistance, and 24/7 patient assistance; and care management support services including nutrition guidance. The company was incorporated in 2017 and is based in Fort Myers, Florida.

American Oncology Network, Inc. trades as AONC on OTC. The company is classified in Healthcare / Medical - Care Facilities and reports in USD.

The current profile places the business in Medical - Care Facilities. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $1.76B of revenue and -$3.97M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

American Oncology Network, Inc. can be compared against peers such as Benchmark Holdings plc, 3-D Matrix, Ltd., China Evergrande New Energy Vehicle Group Limited, Hansa Biopharma AB (publ), Mayne Pharma Group Limited, Medical Facilities Corporation.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $350.98M, beta of 0.51, and return on equity of -21.2%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

AONC currently shows total debt of $147.37M and beta of 0.51. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: 10-K (2025-03-27 00:00:00), 15-15D (2025-01-02 00:00:00), 8-K/A (2024-12-26 00:00:00), 8-K (2024-12-19 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.aoncology.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.